DermBiont

DermBiont develops skin microbiome therapeutics platform to treat and prevent skin diseases. It is leveraging skin microbiome therapeutics to advance its lead live bacterial product, DBI-001, in clinical trials for the treatment of fungal skin infections, beginning with interdigital athlete’s foot, moccasin athlete’s foot, and onychomycosis.